Spanish pharmaceutical firm Almirall has called on Quintiles to help promote its respiratory drug portfolio in the UK.
The marketing deal will include Eklira Genuair, a new long-acting antimuscarinic (LAMA) obstructive pulmonary disease (COPD) developed by Almirall which was approved by European regulators last week
The agreement - terms of which were not disclosed - builds on the firms’ existing relationship that has seen Quintiles play a part in European clinical trials of the drug and provide market access service in a range of countries.
The growing market access and commercialisation services sector has been a particularly active area for Quintiles so far this year.
Since January the pharma services firm has expanded its commercialisation business to North Africa and the Middle East , signed a deal to support Delcath’s efforts in Europe and established a commercial solutions unit in Brazil .
It is unclear if Quintiles will play a role in promoting Eklira Genuai in the US – where it will be sold by Almirall’s partner Forest Laboratories as Tudorza Pressair having been cleared by the US Food and Drug Administration (FDA) earlier this month.